by EpicentRx | Apr 4, 2024 | 2024, Press Releases
Compelling clinical data demonstrate that AdAPT-001, which delivers a TGF-β trap to tumors, reverses established resistance to checkpoint inhibitors and makes checkpoint inhibitors more active SAN DIEGO, April 2, 2024 /PRNewswire/ — EpicentRx, Inc, a...
by EpicentRx | Apr 1, 2024 | Company Updates
This being a leap year, EpicentRx leapt into action in Q1. In January, which is named after the two-faced Roman God, Janus, who focused simultaneously on the past and the future, EpicentRx made sure to look back even as it moved forward. February, the leap month, was...
by EpicentRx | Feb 22, 2024 | Conferences
January 2024; Silicon Valley, California Oral Presentation: AdAPT-001 in Advanced Soft-Tissue Sarcoma (BETA PRIME) Learn more